Bioavailability and Food Effects of HRS-7535 Tablets With Different Formulating Processes in Healthy Subjects - Trial NCT06422039
Access comprehensive clinical trial information for NCT06422039 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shandong Suncadia Medicine Co., Ltd. and is currently Not yet recruiting. The study focuses on Type 2 Diabetes Mellitus. Target enrollment is 18 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shandong Suncadia Medicine Co., Ltd.
Timeline & Enrollment
Phase 1
May 15, 2024
Jun 15, 2024
Primary Outcome
PK parameters๏ผCmax,PK parameters๏ผAUC0-t,PK parameters๏ผAUC0-โ,Relative bioavailability of HRS-7535 (D) tablets compared to HRS-7535 (C) tablets following a high-fat meal,Relative bioavailability of HRS-7535 (D) tablets under both fasting and fed (high fat meal) status
Summary
This study was designed as a a single-center, randomized, open, interleaved (3-cycle,
 3-sequence) trial. It is planned to enroll 18 healthy subjects.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06422039
Non-Device Trial